Huang Tingting,Qiu Hong,Yuan Xianglin. Targeted therapy of gastric cancer: current and prospective strategies. Oncol Transl Med, 2018, 4: 41-47.
Targeted therapy of gastric cancer: current and prospective strategies
Received:March 30, 2018  Revised:May 17, 2018
View Full Text  View/Add Comment  Download reader
KeyWord:gastric cancer; targeted therapy; clinical trials
Author NameAffiliationE-mail
Huang Tingting Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology huangttcx@163.com 
Qiu Hong Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology  
Yuan Xianglin Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology xlyuan1020@163.com 
Hits: 4094
Download times: 8304
Abstract:
      Gastric cancer is the third leading cause of cancer-related death worldwide. Surgery is currently the only curative treatment strategy. Chemotherapy has shown limited efficacy in advanced gastric cancer patients with a median overall survival of less than one year. Thus, new treatments are urgently needed. Trastuzumab and Ramucirumab are the only targeted therapies approved currently. Most Phase III clinical trials evaluating targeted drugs in gastric cancer have failed. This review will evaluate relevant clinical trials with targeted therapies performed in gastric cancer patients, discuss the possible reasons for the failure, and indicate new possibilities to enhance gastric cancer treatment.
Close